1. Home
  2. THH vs INAB Comparison

THH vs INAB Comparison

Compare THH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

THH

TryHard Holdings Limited Ordinary Shares

N/A

Current Price

$0.39

Market Cap

17.1M

Sector

N/A

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.39

Market Cap

14.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
THH
INAB
Founded
2013
2016
Country
Japan
United States
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.1M
14.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
THH
INAB
Price
$0.39
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
924.9K
71.4K
Earning Date
05-19-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$305.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$0.12
52 Week High
$56.26
$4.20

Technical Indicators

Market Signals
Indicator
THH
INAB
Relative Strength Index (RSI) 40.78 40.94
Support Level $0.31 $1.17
Resistance Level $0.55 $2.14
Average True Range (ATR) 0.05 0.14
MACD 0.12 -0.01
Stochastic Oscillator 36.81 12.31

Price Performance

Historical Comparison
THH
INAB

About THH TryHard Holdings Limited Ordinary Shares

Tryhard Holdings Ltd is a Japan-based lifestyle entertainment company offering services across the entertainment and hospitality sectors. Its main businesses include event curation, consultancy and management, sub-leasing of venues, and restaurant operations. The company operates through four segments, with the majority of revenue generated from consultancy and management, which provides club planning, operations, event production, entertainer bookings, and sponsorship services. The event curation segment produces both in-house and client events; the sub-leasing segment rents venues and sub-leases them to clubs; and the restaurants segment operates themed dining outlets that complement its entertainment offerings.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: